Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
15 September 2024
| Name: | RESAPP HEALTH LIMITED (RAP) | ||||||
| ISIN: | AU000000RAP5 | ||||||
| Date of Listing: | 12 January 2005 | ||||||
| Date of Delisting: | 27 September 2022 | ||||||
| Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 27 September 2022.Legal Status:
ACN: 094 468 318ABN: 51 094 468 318
Registration Date: 13 September 2000
Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| RESAPP HEALTH LIMITED | 08/07/2015 | |
| NARHEX LIFE SCIENCES LIMITED | 08/07/2015 |
REGISTRY:
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
delisted at entity's request under Listing Rule 17.11 | 27/09/2022 |
we understand Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) acquired all of the issued shares in RAP for $0.207 cash per share | 27/09/2022 |
The company releases a notification of cessation of securities. | 16/09/2022 |
The securities of ResApp Health Limited will be suspended from quotation at the close of trading on Thursday, 15 September 2022 under Listing Rule 17.2, following lodgement of the Supreme Court of New South Wales orders with ASIC approving the scheme of arrangement by which Pfizer Australia Holdings Pty Limited will acquire all of the issued shares in RAP. | 15/09/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement. | 14/06/2022 |
ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration). Relative to ResApp's share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: 130.0% based on the Confirmed Data Consideration, 62.2% based on the Unconfirmed Data Consideration. Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders. The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme. | 14/06/2022 |
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the update on the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Tuesday 14 June 2022. | 08/06/2022 |
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Wednesday 8 June 2022. | 06/06/2022 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement. | 02/06/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding its COVID-19 study results. | 22/03/2022 |
92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm "“ exceeding the real-world measured sensitivity of rapid antigen testing. Initial market opportunities in settings where frequent testing is required "“ employee, healthcare worker and student screening, travel, sports, entertainment, and aged care. ResApp to engage with regulators on requirements for approvals and seek to partner with a global health or technology company to accelerate commercialisation. | 22/03/2022 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results. | 21/03/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement. | 30/10/2018 |
The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease. | 30/10/2018 |
Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018. | 29/10/2018 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis. | 24/10/2018 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement. | 09/08/2017 |
The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds. | 09/08/2017 |
The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study. | 02/08/2017 |
The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP | 09/07/2015 |
name changed from Narhex Life Sciences Limited | 08/07/2015 |
delisted at entity's request under Listing Rule 17.11 | 27/09/2022 |
we understand Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) acquired all of the issued shares in RAP for $0.207 cash per share | 27/09/2022 |
The company releases a notification of cessation of securities. | 16/09/2022 |
The securities of ResApp Health Limited will be suspended from quotation at the close of trading on Thursday, 15 September 2022 under Listing Rule 17.2, following lodgement of the Supreme Court of New South Wales orders with ASIC approving the scheme of arrangement by which Pfizer Australia Holdings Pty Limited will acquire all of the issued shares in RAP. | 15/09/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement. | 14/06/2022 |
ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration). Relative to ResApp's share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: 130.0% based on the Confirmed Data Consideration, 62.2% based on the Unconfirmed Data Consideration. Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders. The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme. | 14/06/2022 |
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the update on the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Tuesday 14 June 2022. | 08/06/2022 |
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Wednesday 8 June 2022. | 06/06/2022 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement. | 02/06/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding its COVID-19 study results. | 22/03/2022 |
92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm "“ exceeding the real-world measured sensitivity of rapid antigen testing. Initial market opportunities in settings where frequent testing is required "“ employee, healthcare worker and student screening, travel, sports, entertainment, and aged care. ResApp to engage with regulators on requirements for approvals and seek to partner with a global health or technology company to accelerate commercialisation. | 22/03/2022 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results. | 21/03/2022 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement. | 30/10/2018 |
The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease. | 30/10/2018 |
Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018. | 29/10/2018 |
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis. | 24/10/2018 |
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement. | 09/08/2017 |
The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds. | 09/08/2017 |
The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study. | 02/08/2017 |
The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP | 09/07/2015 |
name changed from Narhex Life Sciences Limited | 08/07/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 15/03/2021 | Roger Aston | 290,000 | $0.070 | $20,300 | |
| 15/03/2021 | Anthony Keating | 225,000 | $0.072 | $16,200 | |
| 15/03/2021 | Chris Ntoumenopoulos | 500,000 | $0.071 | $35,500 | |
| 05/10/2017 | Brian Leedman | 875,885 | $0.074 | $64,512 | |
| 09/08/2017 | Chris Ntoumenopoulos | 1,000,000 | $0.073 | $72,822 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Roger Aston | Non Exec Chairman | 17/07/2015 |
| Anthony Keating | Managing Director, CEO | 02/07/2015 |
| Chris Ntoumenopoulos | Non Exec Director | 22/01/2015 |
| Robert Ramsay | Non Exec Director | 20/12/2013 |
| Michael Stein | Non Exec Director | 06/04/2020 |
| Brian Leedman | Executive Director | 22/02/2016 |
| Nicki Farley | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Nathan Buzza | Non Exec Director | 29/12/2017 | 31/03/2020 |
| Adam Sierakowski | Non Exec Director, Non Exec Director | 16/05/2013 | 22/03/2016 |
| Cyril D'Silva | Executive Chairman | 16/05/2013 | 22/01/2015 |
| Peter Christie | Chairman | 13/01/2011 | 20/12/2013 |
| David Mandel | Director | 17/05/2010 | 20/12/2013 |
| Simon Lill | Director | 13/01/2011 | 20/12/2013 |
| Ian Reynolds | Director | 22/02/2013 | 30/04/2013 |
| Peter Nash | Director | 07/10/2004 | 22/06/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
